In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $64.56 in the last session, down -0.68% from day before closing price of $65.0. In other words, the price has decreased by -$0.68 from its previous closing price. On the day, 2.35 million shares were traded. ARWR stock price reached its highest trading level at $67.0 during the session, while it also had its lowest trading level at $63.4501.
Ratios:
We take a closer look at ARWR’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 56.30. For the most recent quarter (mrq), Quick Ratio is recorded 4.86 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 1.57 whereas as Long-Term Debt/Eq ratio is at 1.47.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 ’26 when O’Brien Patrick sold 49,493 shares for $63.11 per share. The transaction valued at 3,123,349 led to the insider holds 474,908 shares of the business.
Hamilton James C sold 40,164 shares of ARWR for $2,534,661 on Jan 05 ’26. The Chief Medical Officer now owns 171,958 shares after completing the transaction at $63.11 per share. On Jan 02 ’26, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 13,187 shares for $66.10 each. As a result, the insider received 871,703 and left with 3,792,739 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 8970773504 and an Enterprise Value of 8631744512. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.65 while its Price-to-Book (P/B) ratio in mrq is 18.80. Its current Enterprise Value per Revenue stands at 10.407 whereas that against EBITDA is 70.593.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.22, which has changed by 2.4140666 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $76.76, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 15.63%, while the 200-Day Moving Average is calculated to be 119.40%.
Shares Statistics:
According to the various share statistics, ARWR traded on average about 2.56M shares per day over the past 3-months and 3259700 shares per day over the past 10 days. A total of 135.70M shares are outstanding, with a floating share count of 125.87M. Insiders hold about 7.28% of the company’s shares, while institutions hold 81.37% stake in the company. Shares short for ARWR as of 1765756800 were 10234550 with a Short Ratio of 4.00, compared to 1763078400 on 11596104. Therefore, it implies a Short% of Shares Outstanding of 10234550 and a Short% of Float of 9.7799994.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of Arrowhead Pharmaceuticals Inc (ARWR) in the stock market.The consensus estimate for the next quarter is -$0.89, with high estimates of $0.43 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$1.55 and -$5.93 for the fiscal current year, implying an average EPS of -$3.46. EPS for the following year is -$4.54, with 8.0 analysts recommending between -$1.54 and -$6.77.
Revenue Estimates
According to 9 analysts,. The current quarter’s revenue is expected to be $225.66M. It ranges from a high estimate of $425.29M to a low estimate of $9M. As of. The current estimate, Arrowhead Pharmaceuticals Inc’s year-ago sales were $2.5MFor the next quarter, 9 analysts are estimating revenue of $57M. There is a high estimate of $209M for the next quarter, whereas the lowest estimate is $1.8M.
A total of 13 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $599.56M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $389.56M. In the same quarter a year ago, actual revenue was $829.45MBased on 11 analysts’ estimates, the company’s revenue will be $276.56M in the next fiscal year. The high estimate is $478M and the low estimate is $114.2M.
